Review Article
Can Circulating Cell-Free DNA or Circulating Tumor DNA Be a Promising Marker in Ovarian Cancer?
Table 1
An overview of the research studies on ctDNA/ctDNA in ovarian cancer is summarized.
| Author | Year | Application | Sample | Method | Target |
| Shao et al. [31] | 2015 | Diagnosis | Serum | bDNA technique | The levels of cfDNA | Kamat et al. [32] | 2006 | Diagnosis | Plasma | Real-time PCR | The levels of cfDNA | Capizzi et al. [33] | 2008 | Diagnosis/therapy response | Plasma | Real-time PCR | The levels of cfDNA | Pereira et al. [34] | 2015 | Diagnosis | Serum | Droplet digital PCR | The levels of ctDNA | Zhou et al. [35] | 2016 | Diagnosis | Peripheral blood | Quantitative real-time PCR | The levels and integrity of cfDNA | Stamenkovic et al. [36] | 2020 | Diagnosis | Peripheral blood | Quantitative real-time PCR | The levels and integrity of cfDNA | Yu et al. [37] | 2019 | Diagnosis | Peripheral blood | Quantitative real-time PCR | The levels and integrity of cfDNA | Otsukaet al. [38] | 2004 | Diagnosis | Plasma | F-SSCP | TP53 mutations | Park et al. [39] | 2018 | Diagnosis | Plasma | Digital PCR | TP53 mutations | Swisher et al. [40] | 2005 | Diagnosis | Peripheral blood | Ligase detection reaction | TP53 mutations | Battagli et al. [41] | 2004 | Diagnosis | Peripheral blood | MSP | BRCA1 and RASSF1A methylation | Dvorská et al. [42] | 2019 | Diagnosis | Plasma | MSP | Gene methylation | Wu et al. [43] | 2014 | Diagnosis | Serum | MSP | RASSFA methylation | Sandeep et al. [44] | 2019 | Diagnosis | Plasma | MSP | RASS1A and BRCA1 methylation | Li et al. [45] | 2019 | Diagnosis | Peripheral blood | NGS | Qualitative detection (methylation) | Wang et al. [46] | 2017 | Diagnosis | Serum | MSP | OPCML methylation | Liggett et al. [47] | 2011 | Diagnosis | Serum | NGS | DNA methylation | Widschwendter et al. [48] | 2017 | Diagnosis | Serum | Bisulfite sequencing | DNA methylation | Vanderstichele [49] | 2017 | Diagnosis | Plasma | Low-coverage whole-genome sequencing | Chromosomal instability | Cheng et al. [50] | 2009 | Therapy response | Plasma | Quantitative PCR | The levels of cfDNA | Kamat et al. [51] | 2006 | Therapy response | Plasma | Real-time PCR | The levels of cfDNA | Hufnagl et al. [52] | 2020 | Therapy response | Plasma | Quantitative RT-PCR | The levels of cfDNA | Arend et al. [53] | 2018 | Therapy response | Plasma | NGS | Mutations | Vitale et al. [54] | 2020 | Therapy response | Serum | NGS | TP53 mutations | Kim et al. [55] | 2019 | Therapy response | Plasma | Digital PCR | TP53 mutations | Parkinson et al. [56] | 2016 | Therapy response | Plasma | Microfluidic digital PCR | TP53 mutations | Harris et al. [57] | 2016 | Therapy response | Plasma | Quantitative PCR | Chromosomal rearrangements | Morikawa et al. [58] | 2018 | Therapy response | Plasma | Droplet digital PCR | PIK3CA and KRAS mutations | Christie et al. [59] | 2017 | Therapy response | Plasma | NGS | BRCA1/2 germline mutations | Steffensen et al. [60] | 2014 | Therapy response/prognosis | Plasma | Real-time PCR | The levels of cfDNA | Ratajska et al. [61] | 2017 | Therapy response | Plasma | NGS | BRCA1/2 mutations | Weigelt et al. [62] | 2017 | Therapy response | Plasma | NGS | BRCA1 and BRCA2 reversion mutations | Kamat et al. [63] | 2010 | Prognosis | Plasma | Real-time PCR | The levels of cfDNA | No et al. [64] | 2012 | Prognosis | Serum | Quantitative real-time PCR | The levels of cfDNA | Phallen et al. [65] | 2017 | Prognosis | Plasma | TES-seq | Genomic mutations | Dobrzyckaet al. [66] | 2011 | Prognosis | Plasma | PCR-RFLP | KRAS and TP53 mutations | Zhuang et al. [67] | 2017 | Prognosis | Peripheral blood | Meta-analysis | KRAS mutation | Giannopoulou et al. [68] | 2018 | Prognosis | Plasma | Real-time MSP | ESR1 methylation | Giannopoulou et al. [69] | 2017 | Prognosis | Plasma | Real-time MSP | RASSF1A methylation |
|
|